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Protein kinase signalingHepatocyte growth factor (HGF) is a chemoattractant and inducer for neural stem/progenitor (NS/P) cell
migration. Although the type II transmembrane serine protease, matriptase (MTP) is an activator of the
latent HGF, MTP is indispensable on NS/P cell motility induced by the active form of HGF. This suggests
that MTP's action on NS/P cell motility involves mechanisms other than proteolytic activation of HGF.
In the present study, we investigate the role of MTP in HGF-stimulated signaling events. Using speciﬁc
inhibitors of phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt) or focal adhesion kinase (FAK),
we demonstrated that in NS/P cells HGF-activated c-Met induces PI3k-Akt signaling which then leads to
FAK activation. This signaling pathway ultimately induces MMP2 expression and NS/P cell motility.
Knocking down of MTP in NS/P cells with speciﬁc siRNA impaired HGF-stimulation of c-Met, Akt and FAK
activation, blocked HGF-induced production of MMP2 and inhibited HGF-stimulated NS/P cell motility.
MTP-knockdown NS/P cells cultured in the presence of recombinant protein of MTP protease domain or
transfected with the full-length wild-type but not the protease-defected MTP restored HGF-responsive
events in NS/P cells. In addition to functioning as HGF activator, our data revealed novel function of MTP
on HGF-stimulated c-Met signaling activation.
© 2014 Published by Elsevier B.V.1. Introduction
Neural stem/progenitor (NS/P) cell migration is one important
process in neurogenesis. In adult brain, NS/P cells generated in the
subventricular zone (SVZ) of the lateral ventricle or in dentate gyrus
subgranular zone of the hippocampus migrate to their destination and
mature to functional neurons [1,2]. It was reported that streams of
migrating neuroblasts are attracted by and move toward to the in-
jured sites after brain injury [3–7]. Factors such as stromal-derived
factor-1α (SDF-1α) [8,9], vascular endothelial growth factor (VEGF)
[10,9], stem cell factor (SCF) [11] and recently hepatocyte growth
factor (HGF) [12,13,9] have been shown to be chemoattractants for
NS/P cell migration.
HGF is a multifunctional molecule. Binding to the cell surface
receptor c-Met, HGF induces phosphorylation of c-Met at several
tyrosine residues which provide docking sites for several intracellular/progenitor; HGF, hepatocyte
rotein kinase B
earch Institutes Grant 00A1-
fax: +886 37 587408.signaling molecules [14]. Activation of c-Met downstream signaling
molecules subsequentlymediates several important physiological func-
tions including development, cell mitogenesis [15], motogenesis [15,
16], and morphogenesis [17–19]. HGF is also involved in metastasis of
cancers of various tissue origins [20]. HGF is synthesized and secreted
as an inactive single-chain protein that requires proteolytic cleavage
at a speciﬁc site for activation. A number of membrane-associated and
secreted typsin-like serine proteases acting as HGF activator have
been identiﬁed [21–24] including the type II transmembrane serine
protease, matriptase (the mouse homolog is termed epithin) [25].
Matriptase (MTP) is composed of a short cytoplasmic N-terminal
region, a single transmembrane domain, an extracellular region con-
tainingmultiple repeats of CUB and LDLR domains and a serine protease
domain [26]. MTP is present on the surface of a broad range of epithelial
cells [27,28]. It is an auto-activating protease [29] and has been shown
to be involved in cancer progression [30–33], in epidermal homeostasis
[34,35], and in neural tube development [36,37] in part through proteo-
lytic activation of its substrate proteins [38]. We have previously dem-
onstrated that MTP is expressed in NS/P cells and is a critical factor
on NS/P cell mobilization induced by SDF-1α, VEGF and HGF [9]. The
precise mechanism of MTP on the chemotactic effect of these agents,
however, was not clear. Although MTP is thought to be involved
in HGF-mediated functions by acting as its proteolytic activator
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the active form of HGF also critically depends on MTP [9]. This observa-
tion suggests that MTP participates in HGF-stimulated NS/P cell mobili-
zation through mechanisms other than proteolytic activation of HGF.
We reasoned that MTP in NS/P cells could modulate the activation of
HGF-responsive motogenic signaling. The present study was aimed to
determine the role/mechanisms of MTP on HGF-stimulated motogenic
signaling events in NS/P cells.
2. Materials and methods
2.1. Cell culture
NS/P cell was differentiated from Sox1-GFP knock-in embryonic
stem cells (46C ES cell) (obtained from Dr. Austin Smith in University
of Edinburgh) as described previously [9]. In brief, 46C ES cells were
routinely propagated on 0.1% gelatin-coated Petri dishes without feeder
cells in Glasgow modiﬁcation of Egale's medium (from Invitrogen
Life Technology) supplemented with 1% FBS, 10% KSR, 0.1 mM 2-ME,
2 mM glutamine, 1 mM sodium pyruvate and 20 ng/ml leukemia
inhibitory factor (from Millipore Corporate, Billerica, MA, USA)
[41]. To obtain NS/P cells, 46C cells were dissociated and cultured
in neuronal differentiation medium composed of DMEM/F15 (50:50)
1:1 with neural basal medium supplemented with modiﬁed N2, B27
and 50 μg/ml BSA-V (all from Invitrogen). The SOX1-GFP positive
neurospheres were used in all assays. Characterization of the SOX1-
GFP positive NS/P cells was described previously [9,41]. The mouse
brain endothelial cells bEnd.3 were purchased from Bioscience Collec-
tion and Research Center (Hsinchu, Taiwan, R.O.C.) and were cultured
in DMEM supplemented with 10% FBS as described previously [42].
For HGF stimulation, GFP positive NS/P cells wereﬁrst starved for 4 h
in neuronal differentiation medium without supplements; 40 ng/ml of
the active, two-chain form recombinant HGF (PeproTech Inc., Rocky
Hill, NJ, USA) was added and cells were harvested after incubation for
an indicated period of time. In cultures that kinase inhibitors were test-
ed, cells were pre-treated with inhibitors prior to HGF treatment. In ex-
periments that the recombinant catalytic serine protease domain of
mouse MTP (Figs. 5 and 6) was tested, the recombinant protein was
added immediately before HGF stimulation. PI3K inhibitor LY294002
and Akt inhibitor VIII (a potent and selective inhibitor for basal and
stimulated phosphorylation/activation of Akt1/Akt2) were used at
50 uM and 10 uM, respectively (both are from Sigma, St. Louis, MR,
USA). FAK-speciﬁc inhibitor 14 (a selective FAK inhibitor can prevent
FAK autophosphorylation at Y397) (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) was used at 100 uM [43]. C-Met inhibitor
crizotinib was purchased from Sigma. The recombinant protein
of mouse MTP protease domain was purchased from R&D System
(Minneapolis, MN, USA).
2.2. MTP expression plasmid and in vitro site-directed mutagenesis
MTP cDNA clone was purchased from I.M.A.G.E. consortium; DNA
sequencing analysis conﬁrmed the presence of full-length MTP cDNA.
The coding region of MTP was then ampliﬁed from the I.M.A.G.E. clone
using a forward primer containing BamHI sequences ﬂanking the ﬁrst
ATG and a reverse primer containing XbaI sequences ﬂanking the
end codon of MTP protein. The resulting BamHI–XbaI fragment of MTP
coding region was then cloned into pcDNA3.1/myc-His(−) vector
(Invitrogen) at the same restriction sites. Point mutation in MTP coding
region was introduced using QickChange II XL system (Stratagene
Division, Agilent Technologies, Lo Jolla, CA, USA) following the protocol
provided by the manufacturer. Brieﬂy, primers containing required
point mutation were annealed to pcDNA3.1/myc-His(−) vector
(Invitrogen) carrying full-length MTP coding region. After primer
extension in thermal cycler, the parental DNA template was digested
with Dpn I endonuclease, and the mutation-containing DNA wastransformed into competent cells for nick repair and plasmid ampli-
ﬁcation. Mutagenic primers carrying mutation within the sequences
of MTP–siRNA recognition site without changing the protein coding
sequences was used ﬁrst to make MTP that is not affected by MTP-
speciﬁc siRNA. The resulted siRNA-resistant MTP-expressing plas-
mid was then used as a template to generate a catalytically inactive
MTP with primers containing mutation changing Serine residue
805 in MTP catalytic triad of the protease domain to Alanine [44].
The sequences of MTP–siRNA mutant primer are 5′-TTCCGAAGCTTT
GATGTGGCACCGTGTGATGAGCAG-3′. The mutated nucleotides are
underlined. The sequences of the primer for inactive protease are
5′-GACTCCTGCCAGGGTGACGCTGGTGGCCCCTTGTCAA-3′. Mutated
nucleotide is underlined which changes Serine to Alanine.
2.3. siRNA and plasmid DNA transfection
Transfection of siRNA or plasmid DNA was performed using
Lipofectamine 2000 as described previously [9]. Preparation of MTP-
expressing plasmid was described in Section 2.2. The control siRNA
with no target, the siRNA against gene encoding mouse MTP and
Lipofectamine 2000 were all purchased from Invitrogen. Most GFP-
positive NS/P cells were successfully transfected with siRNA after 48 h
of incubation as monitored using ﬂuorescently labeled siRNA. MTP
knockdown or overexpression efﬁciency was checked by RT-PCR.
2.4. Western blot and densitometric quantitation
Cells were lysed by freeze-and-thaw in Tris–HCl buffer (pH 7.5)
containing Triton, protease inhibitors and phosphatase inhibitors as
described previously [39]. Protein concentrations were determined by
SuperSignal® West Pico protein assay kit (Pierce, Rochford, IL) using
bovine serum albumin as a standard. An equal amount of protein was
subjected to SDS-PAGE, followed by Western blot as described previ-
ously [39]. For quantitation, X-ray ﬁlms of Western immunoblots were
scanned; the integrated absorbance corresponding to the area of the
speciﬁc protein was recorded with Image J software. The corresponding
absorbance of phosphorylated protein was adjusted to that of the
total protein of the same molecule. Only the protein bands within
the linear range of the X-ray ﬁlm exposure were taken into quantita-
tive measurement. Antibody to FAK and phospho-FAK (Y397) was
from Cell Signaling (Cell Signaling Technology Inc., Danvers, MA,
USA); antibodies to actin, Akt, phospho-Akt (S473) and phospho-
cMet (Y1230/1234/1235) were from Millipore (Millipore Corporate,
Billerica, MA, USA); antibody to total c-Met was from Santa Cruz
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); antibody to
MMP2 was purchased from Calbiochem (EMD Millipore).
2.5. Flow cytometer analysis of c-Met phosphorylation in cells
Cells were collected, ﬁxed and permeabilized in darkness for 30min
at room temperature. Cells were then washed and incubated with
phospho-Met antibody (Y1234/1235) (Cell Signaling Technology Inc.,
Danvers, MA, USA) or control immunoglobin. After incubation with
PE-conjugated 2nd antibody (eBioscience, Inc., San Diego, CA, USA),
the labeled cells were analyzed by BD Caliber FACS (BD Biosciences,
San Jose, CA, USA) at National Health Research Institutes core facility.
Ten thousands of cells from each sample were assayed. Histograms of
these assays were generated using FlowJo software (Tree Star Inc.,
Ashland, OR, USA).
2.6. RNA isolation and reverse transcription-polymerase chain reaction
(RT-PCR)
RNA isolation and RT-PCR were carried out as previously described
[9]. Gene-speciﬁc primers were as follows: S15 (mouse ribosomal
protein S15): forward 5′-TTCCGCAAGTTCACCTACC-3′, reverse 5′-TGCT
Fig. 1.HGF stimulates c-Met, Akt and then FAK activation in NS/P cells. A. Silver staining of HGF protein separated by electrophoresis under denatured condition. Arrows point the alpha
(about 69 kDa) and beta (around 33 kDa) chains of the activated HGF. B. Unstimulated NS/P cells (0′), NS/P cells stimulatedwith the active form of HGF for 10, 30 or 60min (10′, 30′ and
60′ respectively) were subjected toWestern immunoblot using antibody speciﬁc for phosphorylated (*cMet) or total cMet protein (cMet). Graphs show the quantitation of chemilumi-
nescence by densitometry ofWestern blot. The level of cMet phosphorylation in each treatment was normalized to its total protein. Values of all HGF-stimulated cells were then normal-
ized to that of the non-stimulated cell that is set at 1. Data aremean±SDof 3 independent experiments. C. Flowcytometer analysis of c-Met phosphorylation inNS/P cells. Red curve is the
control cells (no HGF); blue curve is the cells stimulatedwithHGF for 30min (+HGF); orange curve is the cells stimulatedwith HGF in the presence of c-Met inhibitor (+HGF+ cMETi).
The same results were observed in 5 independent experiments. D. Total (FAK and AKT respectively) and phosphorylated FAK and Akt (*FAK and *AKT respectively) in NS/P cells after 0-,
10- or 30-minute treatment with HGF (0′, 10′ and 30′ respectively) in the absence (DMSO) or presence of FAK inhibitor (FAKi), Akt inhibitor (AKTi) or PI3K inhibitor (LY). ACT indicates
the actin that is used as a loading control for Western blot. E shows the quantitation analysis of the phosphorylated FAK by densitometry of the Western blot in C. F is the quantitation
analysis of the phosphorylated Akt by densitometry of the Western blot in C. Densitometry data of cells without treatment, with 30 min of HGF treatment in the absence or presence
of inhibitor for FAK (FAKi), Akt (AKTi) or PI3K (LY) were compared. The value of each phosphorylated protein was normalized to the value of its corresponding total protein. Values of
all treated sampleswere then normalized to that of sampleswithout any treatment that is set at 1. Data aremean±SDof three toﬁve independent experiments. *, P≦ 0.05; ***, P≦ 0.001.
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GCG-3′, reverse 5′-GGATGTCGCCGGTCAGTATTGGTTATCA-3′; MMP2:
forward 5′-ACCATCGAGACCA TGCGG-3′, reverse 5′-CTCCCCCAACACCAFig. 2. HGF-stimulated PI3K–Akt–FAK signaling induces MMP2 expression. A. RT-PCR of MMP2
60′ or 90′ treatmentwith HGF. B.Western blot of MMP2 protein inNS/P cells without (–) or wit
(LY) or Akt inhibitor (Aki). ACT indicates the actin that is used as a loading control for Western
etry. The value ofMMP2proteinwas normalized to that of actin. The value ofMMP2 inHGF-trea
mean ± SD of three independent experiments. *, P ≦ 0.05; ***, P ≦ 0.001.GTGC-3′. For the ectopic MTP, the forward primer is a gene-speciﬁc
sequence and the reverse primer is a sequence of myc epitope on
the plasmid.mRNA (top) and Western blot of MMP2 protein (bottom) in NS/P cells after 0′, 10′, 30′,
h (+) HGF stimulation in the absence (–) or presence of FAK inhibitor (FKi), PI3K inhibitor
blot. Graphs in B show the quantitation ofWestern blot chemiluminescence by densitom-
ted cellswas thennormalized to that of cellswithout any treatment that is set at 1. Data are
Fig. 3. Inhibition of Akt, FAK or PI3K activation blocks HGF-inducedNS/P cellmotility. NS/P
cells stimulated with HGF in the absence (DMSO) or presence of Akt inhibitor (AKTi), FAK
inhibitor (FAKi) or PI3K inhibitor (LY). The cell motility was measured as described in
Methods. Motility of MTP-knockdown NS/P cells (siM) responding to HGF stimulation is
also shown. Data were normalized to that of NS/P cells without treatment that is set
at 1 (shown in dark dotted line). Data are mean ± SD from three to ﬁve independent
experiments. *, P ≦ 0.05; **, P ≦ 0.01; ***, P ≦ 0.001.
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Day-4 Sox1-GFP+ NS/P cell spheroids were dissociated to single
cells with HyClone HyQutase (Thermo Fisher Scientiﬁc, Waltham,
MA, USA). Five thousands of NS/P cells were placed in laminin-
coated upper chamber of the transwell with a pore size of 8 um;
HGF was added in the bottom chamber. After 16 h of culture, the
number of cells that migrated to the bottom chamber was counted.
In cultures that kinase inhibitors were tested, cells were pre-treated
with inhibitors before migration assay.3. Results
3.1. HGF-induced c-Met phosphorylation activates PI3K, Akt and then FAK
in NS/P cells to induce MMP2 expression
Awide range of signaling players involved in cellmotility induced by
HGF have been identiﬁed in various cell types. These include PI3K–Akt,
ERK, and FAK [45–49]. We thus examined whether these are also the
signaling events in NS/P cells activated by HGF. To distinguish from
MTP's action on proteolytic activation of the latent formHGF, the active,
two-chain form of HGF (Fig. 1A) was used in all the experiments. Phos-
phorylation of HGF receptor c-Met (Fig. 1B, *cMet) in NS/P cells was
detected as early as 10 min after HGF treatment (Fig. 1B, 10′ HGF);
it continued to elevate up to 60min of stimulation. C-Met phosphoryla-
tion can also be assayed by ﬂow cytometer. As shown in Fig. 1C a signif-
icant cell population in HGF-treated NS/P cells exhibits high level c-Met
phosphorylation (Fig. 1C, blue curve); this population of cells did
not exist when c-Met inhibitor crizotinib (Fig. 1C, orange curve) or
PHA-665752 (Fang and Lee unpublished observation) was present
during the HGF treatment. Activation of FAK (Fig. 1D, *FAK in DMSO)
and Akt (Fig. 1D, *AKT in DMSO) in NS/P cells is induced by HGF
following similar time course as that of c-Met activation and reachedFig. 4. Knockdown of MTP in NS/P cells impairs HGF-stimulated events. A. RT-PCR of MTP in NS
is the loading control of RT-PCR. B. Western blot analysis of c-Met phosphorylation (*MET) in
(siM)without (–) or with (+) HGF treatment. C. Flow cytometer analysis of c-Met phosphoryla
without HGF treatment. Blue curves show c-Met phosphorylation in siN or siM cells treated wi
Akt (*AKT) or total Akt (AKT) protein, E. phosphorylated FAK (*FAK) or total FAK (FAK) protein
Graphs show the quantitation of Western blot chemiluminescence by densitometry. For gr
corresponding total protein. For graph in F, the value ofMMP2 proteinwas normalized to that o
that is set at 1. Data are mean ± SD of three independent experiments. *, P ≦ 0.05; **, P ≦ 0.01the peak in about a 30-minute treatment. Quantitative analysis
showed that both FAK (Fig. 1E, DMSO) and Akt (Fig. 1F, DMSO)
phosphorylation were induced 3-fold by a 30-minute treatment.
(FAK and Akt phosphorylation in samples without DMSO showed
the same results [Fang and Lee, unpublished observations].) ERK
was not activated by HGF in NS/P cells (Fang and Lee, unpublished
data). Speciﬁc inhibitor for FAK, Akt or PI3K was used to examine
the signaling relationship between these molecules. FAK inhibitor,
as expected, blocked HGF stimulation of FAK phosphorylation
(Fig. 1D and E, FAKi) but had no effect on HGF stimulation of Akt
phosphorylation (Fig. 1D and F, FAKi). Akt inhibitor, on the contrary,
prevented not only Akt but also FAK phosphorylation by HGF (AKTi
in Fig. 1D, E and F). As Akt is the most prominent downstream effec-
tor of PI3K, inhibitor for PI3K prevented HGF-responsive activation
of both Akt and FAK (LY in Fig. 1D, E and F). These data demonstrated
that in NS/P cells, HGF-stimulated c-Met phosphorylation induces
PI3K–Akt signaling which then activates FAK phosphorylation. We
further found that expression of MMP2, both mRNA and protein,
was induced in NS/P cells following HGF treatment (Fig. 2A). HGF
induction of MMP2 expression did not happen when PI3K, Akt or
FAK inhibitor was present in the culture (Fig. 2B). Evidently, in NS/P
cells, HGF activates c-Met leading PI3K–Akt–FAK signaling pathway
activation which ultimately induces MMP2 expression.
3.2. PI3K, Akt and FAK are involved in HGF-stimulation of NS/P cell motility
We previously have shown that HGF induces NS/P cell motility [9].
Since PI3K–Akt–FAK signaling is activated following HGF-induced
c-Met activation, we examined the effect of these molecules on
HGF-stimulated NS/P cell motility. As shown in Fig. 3, in the presence
of an inhibitor for Akt, FAK or PI3K (AKTi, FAKi and LY, respectively),
HGF failed to induce NS/P cell motility. Evidently, HGF induced NS/P cell
motility through the activation of c-Met downstream PI3K–Akt–FAK
signaling pathway. Inhibiting activation of either of these molecules
completely impaired HGF-induced NS/P cell motility.
3.3. HGF-induced NS/P cell Met–PI3k–Akt–FAK signaling activation and
MMP2 expression are dependent on MTP
Wepreviously showed thatMTP is critical for HGF-induced NS/P cell
motility and that MTP participates in NS/P cell motility in part through
proteolytic activation of MMP2 [9]. Since inhibition of PI3K–Akt–FAK
signaling and knockdown of MTP all prevented HGF-stimulated NS/P
cell motility (Fig. 3)[9], we reasoned that MTP in NS/P cells can partici-
pate in the activation of HGF-responsivemotogenic signaling. The effect
of MTP expression on PI3K, Akt or FAK activation in NS/P cells was then
examined. NS/P cells transfected with the MTP-speciﬁc siRNA greatly
reduced their expression of MTP (Fig. 4A, siM compared with siN) [9].
NS/P cells transfected with the control non-silence siRNA retained
their responses to HGF stimulation and induced c-Met phosphorylation
(Fig. 4B, siN). HGF treatment on MTP-knockdown NS/P cells, however,
did not induce c-Met phosphorylation (Fig. 4B, siM). The same result
was shown byﬂow cytometer analysis: cells containing phosphorylated
c-Met after HGF treatment were observed in NS/P cells transfected
with the non-silence control siRNA (Fig. 4C, siN, blue curve) but not
in NS/P cells transfected with MTP siRNA (Fig. 4C, siM). Akt (Fig. 4D)
and FAK (Fig. 4E) phosphorylation could no longer be induced in
MTP-knockdown NS/P cells by HGF treatment either. Knocking down/P cells transfected with a non-silence siRNA (siN) or with MTP-speciﬁc siRNA (siM). S15
NS/P cells transfected with a non-silence control siRNA (siN) or with MTP-speciﬁc siRNA
tion in cells prepared for B. Red curves show c-Met phosphorylation in siN cells or siM cells
th HGF. Same results were observed in three independent experiments D. Phosphorylated
and F. MMP2 protein in NS/P cells prepared for B. Images show theWestern immunoblot.
aphs in D and E, the value of phosphorylated molecule was normalized to that of each
f actin. The value of HGF-treated samplewas then normalized to that of un-treated sample
; ***, P ≦ 0.001.
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Fig. 6. Exogenous MTP restores HGF stimulation of cell motility in MTP-knockdown NS/P
cells. NS/P cells transfectedwith control siRNA (siN), withMTP-speciﬁc siRNA (siM), with
MTP-speciﬁc siRNAplus expression plasmid containing full-lengthwild-typeMTP (pM) or
plus expression plasmid containing protease inactive MTP (pMN) were subjected to cell
motility assay in the absence (–) or presence (+) of HGF stimulation. “rM” indicates the
motility of cells that was assayed in the presence of the recombinant protein of MTP pro-
tease domain. Datawere normalized to that of NS/P cellswithoutHGF treatment that is set
at 1. Data are mean ± SD from three to ﬁve independent experiments. *, P ≦ 0.05; **,
P ≦ 0.01; ***, P ≦ 0.001.
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(Fig. 4F), in line with the role of MTP in HGF stimulation of Met–PI3k–
Akt–FAK signaling pathway. These observations demonstrated that in
the NS/P cells, MTP is a crucial effector on HGF-stimulated c-Met and
the downstream PI3K–Akt–FAK signaling activation. The effect of MTP,
however, is independent of its role in HGF activation since HGF used
in these experiments are the active, two-chain form of HGF.
3.4. Protease activity of MTP is indispensible for the active form
HGF-induced c-Met, Akt, FAK activation, MMP2 expression and NS/P
cell motility
MTP-knockdownNS/P cells cultured in the presence of the recombi-
nant protein of MTP protease domain regained their ability to activate
Akt (Fig. 5A, rM in siM) and FAK (Fig. 5B, rM in siM) in response
to HGF treatment. To further investigate the inﬂuence of MTP on HGF
stimulation of Akt and FAK activation, we re-expressed MTP in the
knockdown cells and examined its effect on HGF signaling activation.
To ensure expression of the ectopic MTP is not prevented by the
MTP siRNA, a point mutation was introduced into the full-length
MTP cDNA at the siRNA recognition site (described in Section 2.2).
Transfection of this expression plasmid in MTP-knockdown NS/P
cells regained MTP expression in the cells (Fig. 5D, siM + pM). These
cells restored their response to HGF, induced Akt phosphorylation
(Fig. 5A, Akt* in siM + pM+ HGF), FAK phosphorylation (Fig. 5B, FAK*
in siM + pM+ HGF) and MMP2 expression (Fig. 5C, siM + pM). HGF-
induced c-Met activation in the knockdown cells was restored by the
ectopic MTP as well (Fig. 5D, siM + pM). MTP-knockdown NS/P cells
with ectopic expression of the protease-inactive MTP (Fig. 5C,
siM + pMN), however, behaved like their parental MTP-knockdown
cells — they failed to response to the active HGF and could not induce
Akt phosphorylaton (Fig. 5A, siM + pMN), FAK phosphorylation
(Fig. 5B, siM + pMN), MMP2 expression (Fig. 5C, siM + pMN) orFig. 5. Exogenous MTP restores HGF responsive signaling events and MMP2 expression in M
expression in NS/P cells transfected with control siRNA (siN), with MTP-speciﬁc siRNA (siM)
(siM + pM) or plus expression plasmid containing protease inactive MTP (siM + pMN) with
the recombinant protein ofMTPprotease domain. Images areWestern blot of the phosphorylate
actin (ACT). Graphs show the quantitation ofWestern blot chemiluminescence by densitometry
cellswithoutHGF treatment as described in Fig. 4. Data aremean±SDof three independent exp
transfected with control siRNA (siN), with MTP-speciﬁc siRNA (siM), and of ectopic MTP in s
containing protease inactive MTP (siM+ pMN). E. Flow cytometer analysis of c-Met phosphory
without HGF treatment. Blue curves show c-Met phosphorylation in cells treated with HGF.c-Met activation (Fig. 5E, siM + pMN). Consequently, recombinant
protein of MTP protease domain and expression of the MTP but not
the protease-inactive MTP restored HGF-induced cell motility in
knockdown NS/P cells (Fig. 6). These data demonstrated that the
protease activity of MTP is crucial for HGF-induced c-Met activation
and its downstream effects on NS/P cell motility. NS/P cells lacking
MTP lose their ability to induce c-Met activation, and thus are unable to
activate the downstream effectors Akt and FAK, fail to induce MMP2
expression or promote NS/P cell motility.
3.5. Ectopic expression of MTP in brain endothelial cells turns on HGF
induction of c-Met activation
C-Met is the only known receptor for HGF. The ﬁnding that
HGF-stimulation of c-Met activation in NS/P cells requires MTP was
unexpected. We have noticed that the brain endothelial cells although
express c-Met (Fig. 7A, Ctrl, cMET), have little c-Met phosphorylation
after HGF stimulation (Fig. 7A, Ctrl, +HGF, *cMET). Brain endothelial
cells express little MTP (Fig. 7B, Ctrl) [9,42]. We therefore tested if
brain endothelium lacking HGF-responses is due to insufﬁcient MTP
expression. MTP was ectopically expressed in the cells and their c-Met
phsophorylation was examined. Brain endothelial cells transfected
with the plasmid carrying full-length wild-type or the protease-inactive
MTP greatly increased their MTP expression (Fig. 7B pM and pMN
respectively). Cells transfected with the wild-typeMTPwere capable
of phosphorylating c-Met after HGF treatment (Fig. 7A, pM, +HGF,
*cMET). Ectopic expression of the protease-inactive MTP, on the
other hand, was unable to promote HGF-stimulation of c-Met
phosphorylation in brain endothelial cells (Fig. 7A, pMN, +HGF,
*cMET). These data support the observations in NS/P cells that
MTP protease activity is important for HGF-induced c-Met activation
and the effect of MTP on c-Met activation is independent of its function
on HGF activation.
4. Discussion
In the present studies, using ES cell-derived NS/P cell culture system,
we demonstrate that the chemotactic effect of HGF on NS/P cell
migration is through c-Met induced PI3K–Akt–FAKmotogenic signaling
and ultimately the MMP2 expression. PI3K pathway was previously
shown to be a critical convergent point ofmultiple growth factor signal-
ing in human NS/P cells including HGF-induced migration [12]. PI3K is
essential for HGF-stimulated striatal progenitor cell migration [16,50].
Our data support these ﬁndings that PI3K signaling is a major HGF-
stimulated migratory signaling pathway in NS/P system. Our studies
further identify FAK as an important downstream motogenic molecule
of PI3K–Akt signaling in HGF/c-Met induced NS/P cell motility. This
is in contrast to those in other cell types where FAK is upstream of
PI3k–Akt [51]. The most intriguing ﬁnding in our studies is that the
protease activity of MTP is a crucial factor on c-Met activation and sub-
sequently affects c-Met downstream motogenic signaling PI3K–Akt–
FAK activation. MTP can cleave and activate the latent form of HGF
[25]. It has been thought that MTP participates in HGF-mediated func-
tion mainly by activating HGF. The present studies show that MTP
may also participate in c-Met activation. MTP's effect on HGF induction
of c-Met activation in the nervous system may be more common thanTP-knockdown NS/P cells. A. Akt phosphorylation, B. FAK phosphorylation and C. MMP2
, with MTP-speciﬁc siRNA plus expression plasmid containing full-length wild-type MTP
(+) or without (–) HGF stimulation. “rM” indicate cells were cultured in the presence of
d (*AKT, *FAK) protein, the corresponding total protein (AKT, FAK) and the loading control
. The values of the phosphorylatedmolecule in the treated cells were normalized to that of
eriments. *, P≦ 0.05; **, P≦ 0.01; ***, P≦ 0.001. D. RT-PCRof endogenousMTP inNS/P cells
iM cells transfected with expression plasmid containing wild-type MTP (siM + pM) or
lation in NS/P cells prepared for A and B. Red curves show c-Met phosphorylation in cells
Fig. 7. Ectopic MTP turns on HGF-induced c-Met phosphorylation in brain endothelial cells. A. Phosphorylated (*cMET) or total (cMET) c-Met protein in mouse brain endothelial
cells transfected with empty vector (Ctrl), with expression plasmid carrying full-length wild-type MTP (pM) or the protease-inactive MTP (pMN). Cells were starved and then cultured
in the absence (–) or presence (+) of active form HGF. Images show the Western blot and graph shows the densitometry quantitation of Western blot chemiluminescence The value
of phosphorylated protein was normalized to that of total protein; values of pM and pMN cells were then normalized to that of Ctrl cells. Data were collected from 2 to 3 independent
experiments. **, P ≦ 0.01; ***, P ≦ 0.001. B. RT-PCR of MTP in the mouse brain endothelial cells prepared in A. S15 is the loading control of RT-PCR.
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become responsive to HGF by ectopic expression of MTP.
Crosstalk between c-Met and other membrane signaling molecules
such as epithelial growth factor receptor (EGFR), integrins, class B
plexins, the proteoglycan CD44 and G-protein coupled receptors
(GPCR) has been reported [48]. Participation of these molecules in
c-Met activation ensures the speciﬁcity and potency of c-Met-
triggered signaling pathways. Currently, there is no evidence of direct
interaction between MTP and c-Met. EGFR is shown to be cleaved and
become constitutively active by MTP-prostasin cascade in epithelial
cells [52]. Protease activated receptor 2 (PAR2), a member of G-
protein coupled receptors, is shown to be activated by MTP [44] and
this protease cascade system is involved in neural tube closure during
development [37]. It is conceivable that MTP acts on such cross-Fig. 8. Schematic diagram of HGF signaling onNS/P cell mobility and the effects of MTP on
this pathway. NS/P cell motogenic signaling pathway activated by HGF is shown in thin
black arrows. The effects of MTP on this pathway are indicated with thick black arrows
and numbered. Light blue circled “p” indicate phosphorylation.talking signaling molecules to mediate HGF-stimulated c-Met activa-
tion. PAR2, although expressed in NS/P cells, is not involved in MTP-
mediated HGF-stimulated NS/P cell events (Fang and Lee unpublished
observations). Interestingly, brain endothelial cells do not express PAR2
[42]. The direct physical target of MTP linking to c-Met activation re-
mains to be determined. MTP on c-Met activation might be unique
for the neural system since MTP in HGF-regulated mammary epithe-
lial cell morphogenesis [39] and epithelial carcinogenesis [40] is pri-
marily through activation of HGF.
HGF and c-Met are recently reported to be present in the brain
neurogenic SVZ of the lateral ventricle [53] and HGF functions as a
niche factor to promote the proliferation of c-Met-expressing immature
neural stem cells [53]. It is also shown that HGF and c-Met are both
expressed throughout the rostral migratory stream and olfactory bulb
where HGF acts as an inducer and chemoattractant of c-Met-expressing
neuroblast for migration [54]. These data presented in vivo evidences
of HGF/c-Met system functioning in the brain neural stem cell niche.
MTP is expressed in NS/P cells and is present in the ependymal and
sub-ependymal region of lateral ventricle in the adult brain [9].
It represents a passive and effective modulator on NS/P cell functions
[9] and on NS/P cell-brain endothelial communication [42]. Our ﬁnd-
ing added MTP as another possible player to the neurogenic niche.
HGF is a promising agent for brain disease treatment. It is shown to
have neuroprotective effects in the animal model of ischemic brain
injury [55], Alzheimer's disease [56] and Parkinson's disease [57].
MTP's function on modulating HGF signaling may have therapeutic
impact on brain diseases.
The ES cell-derived NS/P cells used in our studies were taken from
the differentiation time point when ES cell to neuronal commitment is
completed [9]. These cells have lost the ES cell identities and exhibit
NS/P cell identities [9]. We did not examine the effect of MTP on ES
cell motility. However, it will not be surprised that MTP can control ES
cell motility. ES cells do express MTP [9]. Cell migration is essential
during embryogenesis and brain development. HGF/c-Met plays a role
in the development of brain [58]. MTP is a member of the protease
cascade during neural tube closure [37].
In summary, we showed that HGF induces NS/P cell motility by
activating c-Met, which leads to PI3K–Akt and then FAK activation
(Fig. 8, thin arrows). Prolong HGF stimulation induces MMP2
1293J.-D. Fang, S.-L. Lee / Biochimica et Biophysica Acta 1843 (2014) 1285–1294expression which further promotes NS/P cell migration (Fig. 8, thin
arrow). MTP modulates HGF-induced NS/P cell motility in a number of
ways. In addition to serve as an activator of latent form HGF (Fig. 8,
thick arrow 1) and latent MMP2 (Fig. 8, thick arrow 3), MTPmediates
c-Met activation (Fig. 8, thick arrow 2), and subsequently the activa-
tion of c-Met downstream PI3K–Akt–FAK signaling to induce cell
movement. As an extra amount of MMP2 is induced by Met–PI3K–
Akt–FAK signaling pathway in NS/P cell, MTP activatesMMP2 to further
promote NS/P motility (Fig. 8, thick arrow 3).References
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